BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 15899812)

  • 1. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
    Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
    Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity.
    Henderson CJ; Pass GJ; Wolf CR
    Toxicol Lett; 2006 Mar; 162(1):111-7. PubMed ID: 16343823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
    Huang Z; Raychowdhury MK; Waxman DJ
    Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
    Gu J; Chen CS; Wei Y; Fang C; Xie F; Kannan K; Yang W; Waxman DJ; Ding X
    J Pharmacol Exp Ther; 2007 Apr; 321(1):9-17. PubMed ID: 17218484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
    Jounaidi Y; Waxman DJ
    Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
    Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
    Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
    Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
    Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
    Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
    J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors.
    Huang Z; Waxman DJ
    Cancer Gene Ther; 2001 Jun; 8(6):450-8. PubMed ID: 11498765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
    Schwartz PS; Chen CS; Waxman DJ
    Cancer Gene Ther; 2003 Aug; 10(8):571-82. PubMed ID: 12872138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
    Jounaidi Y; Hecht JE; Waxman DJ
    Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma.
    Afsharian P; Möllgård L; Hassan Z; Xie H; Kimby E; Hassan M
    Eur J Haematol; 2005 Sep; 75(3):206-11. PubMed ID: 16104876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
    Chen CS; Jounaidi Y; Waxman DJ
    Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
    Chen L; Yu LJ; Waxman DJ
    Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the hepatic CYP reductase null mouse model and its potential application in drug discovery.
    Boggs JW; Hop CE; McNamara E; Deng Y; Messick K; West K; Choo EF
    Mol Pharm; 2014 Mar; 11(3):1062-8. PubMed ID: 24450768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the metabolism of midazolam in C57BL/6J and hepatic reductase null (HRN) mice.
    Grimsley A; Foster A; Gallagher R; Hutchison M; Lundqvist A; Pickup K; Wilson ID; Samuelsson K
    Biochem Pharmacol; 2014 Dec; 92(4):701-11. PubMed ID: 25450676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine.
    Zhang QY; Kaminsky LS; Dunbar D; Zhang J; Ding X
    Drug Metab Dispos; 2007 Sep; 35(9):1617-23. PubMed ID: 17567730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of hepatic cytochrome b
    Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
    Schwartz PS; Chen CS; Waxman DJ
    Cancer Res; 2002 Dec; 62(23):6928-37. PubMed ID: 12460909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.